Exact Sciences Corporation (BIT:1EXAS)

Italy flag Italy · Delayed Price · Currency is EUR
44.91
-1.32 (-2.86%)
At close: Jul 16, 2025
-2.86%
Market Cap8.01B
Revenue (ttm)2.62B
Net Income (ttm)-943.56M
Shares Outn/a
EPS (ttm)-5.10
PE Ration/a
Forward PE82.30
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volumen/a
Openn/a
Previous Close46.23
Day's Rangen/a
52-Week Range39.36 - 51.23
Betan/a
RSI37.46
Earnings DateJul 28, 2025

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Ri... [Read more]

Industry Commercial Physical and Biological Research
Founded 1995
Employees 7,000
Stock Exchange Borsa Italiana
Ticker Symbol 1EXAS
Full Company Profile

Financial Performance

In 2024, Exact Sciences's revenue was $2.76 billion, an increase of 10.37% compared to the previous year's $2.50 billion. Losses were -$1.03 billion, 404.0% more than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.